Condition: Breast Neoplasms · Locally Advanced or Metastatic Breast Cancer · Sponsor: Sun Yat-sen University
It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.
This description comes directly from the study's public registry record.
shusen wang, MD · +86-020-87342693 · wangshs@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Shusen Wang | Guangzhou, Gangdong, China | Recruiting |
| Hunan Cancer Hospital | Hunan, Hunan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05430399